drugset / Trial / NCT01502358
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
Phase 1
Completed
40 enrolled
U.S. Army Medical Research and Development Command
Naval Medical Research Center · collabVical · collabWalter Reed Army Institute of Research (WRAIR) · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether a new investigational dengue vaccine is safe, well-tolerated, and to see if an immune response against dengue disease will be generated.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tetravalent Dengue Vaccine | Vaccine | 1 ml | Intramuscular |
| Background | Vaxfectin | Unknown | 1 ml | Intramuscular |